Navigation Links
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Date:2/25/2009

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis. This patent is also pending in other major markets worldwide.

VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis. A growing body of scientific evidence and data from the VIA-2291 clinical program points to reduction of inflammation and inflammatory processes in the vessel wall as a critical step in combating cardiovascular disease and its complications, including heart attack and stroke.

"Our clinical trial results presented at the most recent meeting of the American Heart Association in New Orleans provides important evidence for VIA-2291's effect on reducing vascular inflammation. This patent is an important step in the commercial development of the compound by providing VIA with exclusivity in this very large and underserved market through 2026," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candida
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... MISSISSAUGA, ON , April 23, 2015 /CNW/ ... major sustainable packaging award from North ... Packaging,s Brandcheck Competitor Comparison won Silver in the ... Awards. The Brandcheck "Competitor Comparison" is ... set of North American and Global peers. This ...
(Date:4/23/2015)... , April 23, 2015 WuXi PharmaTech ... R&D capability and technology platform company serving the pharmaceutical, ... China and the United ... financial results for the first quarter of 2015 after ... 13, 2015 (which will be Thursday morning, May 14, ...
(Date:4/23/2015)... April 23, 2015 Prospects for ... Report Details   We predict the ... of $101.3 billion in 2015 and will grow at a ... the healthcare sectors around the world and increasing functional requirements ... factors in the global healthcare packaging market. A ...
(Date:4/23/2015)... YORK , April 23, 2015  Propanc ... stage healthcare company, focuses on the development of ... cancer. The company lead product includes PRP, a ... trypsinogen and chymotrypsinogen, as well as the enzyme ... is also developing a combination of anti-cancer agents ...
Breaking Biology Technology:WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... April 10 Dedicating this year,s,Venture Forum to the ... announced a partnership in developing and producing the 2008,Life ... and,innovative seed and early-stage life sciences companies from the ... Forum will take place on,May 30, 2008, at the ...
... Medicsight PLC, a,subsidiary of MGT Capital Investments, ... in the development of Computer-Aided Detection (CAD) and ... and diagnosis of,disease, today announced that it has ... Administration ("SFDA") for its MedicRead Colon,workstation. Medicsight will ...
... -, PRINCETON, N.J., April 10, 2008 ... production,company, today announced that it has entered into ... According to the,agreement, Laureate will produce Alopexx,s mAb ... for use in clinical trials, and later,for commercial ...
Cached Biology Technology:Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 2Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 3Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 2Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 22, 2011) - An animal,s behavior is probably ... alike. Its behavior involves processes internal to the animalgenetics, ... and social surroundings. According to the book,s authors, "Animal ... is sparked when neurons fire in response to stimuli ...
... available in German . The ... career researchers in Germany have been chosen. The selection ... Foundation) and the German Federal Ministry of Education and ... male researchers for the Heinz Maier-Leibnitz Prize 2011. The ...
... Research Council (BBSRC) announces the signing of a Memorandum of ... and Technology (MOST) in Vietnam. This heralds the start of ... tolerance in the world,s most important staple food in the ... Funds of up to 350K are being made available by ...
Cached Biology News:New book on animal behavior provides integrated view 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 3Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 4Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 5UK-Vietnam collaboration to improve world's most important staple food 2UK-Vietnam collaboration to improve world's most important staple food 3
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Biology Products: